# Mo-Rez in First- Line (1L) Maintenance Treatment of Non- Homologous Recombination Deficient Ovarian Cancer (HRd OC) [BEHOLD-Ovarian03]

> clinical trial · VERIFIED · 2026-07-10

Status: NOT_YET_RECRUITING · Sponsor: GlaxoSmithKline · Condition: Ovarian Neoplasms

- Company: GlaxoSmithKline
- Sector: Ovarian Neoplasms
- Primary source: https://clinicaltrials.gov/study/NCT07694427

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.